Pharvaris announced abstract acceptances for the 2025 National Summit on hereditary angioedema, featuring multiple poster presentations on deucrictibant.

People living with hereditary angioedema (HAE) often find themselves in a cycle of stress about when the next attack might appear, which may trigger more episodes. Read more.

BOSTON, Mass., July 07, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today ...

Consumer Medicine Information (CMI) about Sacubitril/Valsartan Alphapharm intended for persons living in Australia.

Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of painful and potentially life-threatening swelling of the skin, mucous membranes and internal organs.

Get information on managing hereditary angioedema, including treatment options, symptom control, and strategies to prevent swelling episodes.

What does a hereditary angioedema (HAE) attack look like? An HAE attack can cause swelling of body parts such as the extremities and a red rash that may look like hives.

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema ...

Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein ...

"FDA approves KalVista’s Ekterly for hereditary angioedema" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.